RONALD T. MITSUYASU, M.D.; RICHARD E. CHAMPLIN, M.D.; ROBERT PETER GALE, M.D., Ph.D.; WINSTON G. HO, M.D.; CARL LENARSKY, M.D.; DREW WINSTON, M.D.; MICHAEL SELCH, M.D.; ROBERT ELASHOFF, Ph.D.; JANIS V. GIORGI, Ph.D.; JOHN WELLS, Ph.D.; PAUL TERASAKI, Ph.D.; RONALD BILLING, Ph.D.; STEPHEN FEIG, M.D.
The effects of ex-vivo depletion of T lymphocytes from donor bone marrow using a monoclonal anti-T-cell antibody (CT-2) and complement on the outcome of allogeneic bone marrow transplantation was evaluated in a prospective, randomized, double-blind study of 40 patients with leukemia. Patients receiving T-cell-depleted bone marrow had a lower incidence of acute graft-versus-host disease than control patients (3 of 20 compared with 13 of 20; p = 0.004), and mortality due to acute graft-versus-host disease was reduced. Five patients in the T-cell-depletion group developed graft failure; all control patients had sustained engraftment (p < 0.05). Clinically apparent relapse of leukemia occurred in 7 patients from the T-cell-depletion group and in 2 controls (p, not significant). Cytogenetic evidence of residual leukemia was also detected in the 5 patients with graft failure without overt relapse. Infections and overall survival were similar in the two groups. The effects of T-cell depletion on engraftment and recurrence of leukemia require further evaluation.
MITSUYASU RT, CHAMPLIN RE, GALE RP, et al. Treatment of Donor Bone Marrow with Monoclonal Anti-T-Cell Antibody and Complement for the Prevention of Graft-Versus-Host Disease: A Prospective, Randomized, Double-Blind Trial. Ann Intern Med. 1986;105:20–26. doi: https://doi.org/10.7326/0003-4819-105-1-20
Download citation file:
Published: Ann Intern Med. 1986;105(1):20-26.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use